ADDvise receives frame agreement from SLL at an order value of 20 + 20 MSEK

10-01-2017   Regulatory press release

IM-Medico Svenska AB, a subsidiary in the ADDvise Group, has been awarded a frame agreement for laparoscopy products from the County Council of Stockholm. The estimated value of the agreement for IM-Medico is 10 MSEK per annum. The agreement runs for two years with a two-year prolongation option.

IM-Medico Svenska AB, a subsidiary in the ADDvise Group, has been awarded a frame agreement from the County Council of Stockholm for laparoscopy products. These products are used in laparoscopy procedures with internal stapling for invasive surgery. IM-Medico has been chosen as the preferred supplier in competition with vendors such as Johnsson & Johnsson and Medtronic.

-       Rikard Akhtarzand comments the business; “Our extensive investment in the surgery segment is now paying off. To be chosen as the preferred supplier in competition with Johnsson & Johnsson and Medtronic is a major achievement for us”.

The agreement has a standstill period until January 19 2017 and starts running on June 1 2017.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 


Important information:
 

This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 10, 2017 at 08:45 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com

Latest press releases

Interim report 2025, January 1–June 30

Regulatory

In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses…

Invitation to presentation of interim report April 1 – June 30, 2025

Non-regulatory

ADDvise Group publishes its interim report April 1 – June 30, 2025 on Thursday, July 17, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and CFO, Johan Irwe, will present the report. Webcast If you wish to…

ADDvise announces that the conditions for early redemption of outstanding secured bonds have been fulfilled

Regulatory

ADDvise Group AB (publ) (“ADDvise” or the “Company”) announced on 14 May 2025 that ADDvise intends to redeem the Company’s outstanding senior secured bonds with ISIN SE0020180271 and ISIN NO0013180786 (the “Early Redemption”). The Early Redemption was conditional upon the entering into of the new secured facilities agreement of the equivalence of SEK 450 million…